Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pravastatin · Pravachol

Small molecule · Inhibitor of HMG-CoA reductase (HMGCR) · developed by Bristol Myers Squibb

Approved FDA, Oct 1991
1 Registered trials

What is Pravastatin?

Pravastatin is a synthetic lipid-lowering agent that competitively inhibits hepatic HMG-CoA reductase, the enzyme converting HMG-CoA to mevalonate in cholesterol synthesis. It is studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pravachol
Drug type
Small molecule
Targets
HMG-CoA reductase (HMGCR)
Mechanism
Inhibitor of HMG-CoA reductase (HMGCR)
Pathways
cholesterol synthesis, mevalonate pathway, MHC II suppression on interferon gamma-stimulated antigen-presenting cells
Therapy area
Immunology
Developer
Bristol Myers Squibb
In trials of
LKFT
FDA status
Approved as Pravachol (October 31, 1991), NDA019898

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04608344 Phase 1 Rheumatoid Arthritis Completed LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Other drugs acting on HMGCR

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.